Closely-held xNARA Biologics is reshaping the wellness industry through personalized health and wellness solutions designed to address genetic predispositions and disorders identified by analyzing individual DNA, gut...
Closely held Simtra BioPharma Solutions, a premier contract development and manufacturing organization with more than 65 years of sterile injectable manufacturing experience, offers world-class cGMP sterile fill/finish...
As founder and executive chair of the non-profit Indo-US Organization for Rare Disease (IndoUSrare), Harsha Rajasimha, Ph.D., social entrepreneur, and subject matter expert in bioinformatics, data analysis, and...
Personalis (NASDAQ:PSNL) is developing a liquid biopsy assay designed to detect minimal residual disease (MRD) and cancer recurrence earlier than other diagnostic methods.
Gritstone bio (NASDAQ:GRTS) is expecting in the first quarter of 2024 preliminary data from its Phase 2/3 study evaluating the Company's personalized neoantigen vaccine candidate for the treatment of colorectal cancer...
Closely held Upswing Health, a virtual orthopedic company, is reinventing orthopedic care delivery through its virtual orthopedic musculoskeletal symptom assessment tool and customized pain management program...
Closely held Intrinsic medicine is developing new drugs for diseases that are linked to the disordered interaction of the gut microbiome, the immune system and the nervous system.
Closely held Rainhouse Manufacturing, a company specializing in computer numerical control (CNC) machining, quality assurance, and electronic manufacturing, is working with companies to make their medical device designs...
Closely held Hygieia, a digital therapeutics company for insulin therapy, is reforming how physicians and people with type 2 diabetes manage insulin with its breakthrough proprietary mobile app, d-Nav, which...
Closely held Jeeva Informatics has developed a centralized electronic clinical platform that aims to help clinical trial sponsors increase the efficiency of their clinical trials, while expanding trial access to...